Efficacy and safety of robotic-assisted laparoscopic myomectomy for the treatment of uterine fibroids: an updated literature review

During reproductive years, uterine fibroids are often benign tumors that may have a serious impact on a woman's health. In place of conventional laparoscopic (LM) and abdominal myomectomy (AM) techniques for the treatment of these fibroids, robotic-assisted laparoscopic myomectomy (RALM) is showing promise. This narrative evaluation assesses RALM's safety and effectiveness in comparison to LM and AM. A thorough literature search was carried out with an emphasis on research published between 2018 and 2024 in PubMed, Google Scholar, and Scopus. Hospital stay, surgical complications, operational time, and intraoperative blood loss are among the key outcomes evaluated. In major findings, the review shows that robotic-assisted laparoscopic myomectomy (RALM) performs better than conventional laparoscopic (LM) and abdominal myomectomy (AM) procedures. Comparing RALM to LM and AM, fewer blood transfusions, shorter hospital stays, and less intraoperative blood loss are all related with this approach. Longer operating periods are associated with RALM, but the procedure has a reduced rate of postoperative problems and fewer conversions to open surgery. The lengthier treatment time and increased expenses associated with RALM are still noteworthy factors, despite the advantages it offers in terms of safety and recovery. Therefore, RALM is a safe and efficient surgical alternative for treating uterine fibroids that has a significant positive impact on patient outcomes. To increase accessibility and use of robotic technology, future research should concentrate on cost-effectiveness, long-term efficacy, and technological breakthroughs.